THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS

S. L. Pavlinsky; P. I. Shabalkin

Siberian journal of oncology
Sibirskij onkologičeskij žurnal

ISSN 1814-4861 (Print)
ISSN 2312-3168 (Online)

User

eng | рус

Siberian journal of oncology

Advanced search

Archives

Download this PDF file

Fullscreen

For citations:

Pavlinsky S.L., Shabalkin P.I. THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS. Siberian journal of oncology. 2017;16(4):19-25. (In Russ.) https://doi.org/10.21294/1814-4861-2017-16-4-19-25

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1814-4861 (Print)
ISSN 2312-3168 (Online)

Editor-in-Chief

Evgeny L. Choynzonov

* not an advertisement

Indexing Databases

* not an advertisement

Popular articles

Notifications

Article Tools

Finding References

Email this article (Login required)

Email the author (Login required)

About the Authors

S. L. Pavlinsky
I.I. Mechnikov North-Western State Medical University.
Russian Federation

Pavlinsky Svyatoslav L., MD, DSc, Professor, I.I. Mechnikov North-Western State Medical University.

41, Kirochnaya Street, 191015-Saint-Petersburg, Russia.

P. I. Shabalkin
N.N. Blokhin Russian Cancer Research Center.
Russian Federation

Shabalkin Pavel I., MD, PhD, Researcher, Department of Perspective Development and International Scientific Relations, N.N. Blokhin Russian Cancer Research Center.

24, Kashirskoe shosse, 115478-Moscow, Russia.

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Siberian journal of oncology

For citations:

Cookies policy